Collectively, our analyses suggest that mPCs vulnerable to PBD action can be identified by a composite set of biomarkers that address multiple histological phenotypes, including adenocarcinomas and SCNPC, and utilize genomic markers (RB1, TP53, CHD1, and ATR) and/or phenotypic markers (B7H3, SLFN11, and RepStress scores). This evidence concerns the gene SLFN11 and adenocarcinoma.